Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5311 - PET-CT as a prognostic factor in patients with early stages in primary diagnosed Hodgkin Lymphoma.

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Tumour Site

Lymphomas

Presenters

Tetiana Skrypets

Citation

Annals of Oncology (2018) 29 (suppl_8): viii359-viii371. 10.1093/annonc/mdy286

Authors

T. Skrypets1, O. Novosad2, I. Pastushenko2, T. Kadnikova2, O. Gorbach3, Y. Kmetyuk4, O. Karpova5, L. Mykhalska6, E. Lukjanec7, V. Kozlov8, N. Novikov9, O. Oliinichenko10, N. Kostiukova11, O. Tkachenko11, O. Karnabeda12, V. Stratienko13, I. Kriachok1

Author affiliations

  • 1 Oncohematology, National Cancer Institute of the MPH Ukraine, 03022 - Kiev/UA
  • 2 Oncohematology, National Cancer Institute of the MPH Ukraine, Kiev/UA
  • 3 Experimental Oncology, National Cancer Institute of the MPH Ukraine of the MPH Ukraine, Kiev/UA
  • 4 Radiology, Clinical Hospital «Feofaniya",, v - Kiev/UA
  • 5 Radiology, Clinical Hospital «Feofaniya",, Kiev/UA
  • 6 Hematology, Clinical Hospital «Feofaniya",, Kiev/UA
  • 7 Hematology, Cherkassy Regional Oncology Center, Cherkassy/UA
  • 8 Hematology, Odessa Regional Hospital, 65025 - Odessa/UA
  • 9 Radiology, Oncology Hospital “LISOD”, Kiev/UA
  • 10 Radiology, Center of Nuclear Medicine KMCOC, Kiev/UA
  • 11 Hematology, Kyiv centre of bone marrow transplatation, Kiev/UA
  • 12 Hematology, Oncology Clinic "Innovation", 7352 - Kiev/UA
  • 13 Hematology, Regional Clinical Hospital, Kherson/UA
More

Resources

Abstract 5311

Background

Nowadays, there are different guidelines in diagnostics and PET-guided treatment of lymphomas. But questions about benefits and predictive role of PET-CT in pts with early-stage Hodgkin lymphoma (HL) still remain debatable. Here we report results of Ukrainian multicenter retrospective study about the role of PET-CT in early-stage HL pts.

Methods

56 patients, with stages I-II, were registered in the study between August 2012 and Feb 2018 in 9 Ukrainian hematological centers. Metabolic PET-CT imaging was performed according to standard protocols. The threshold of positivity was set for a residual uptake higher than the liver background (Deauville score (DS) 4and 5). Patients were treated with ABVD or BEACOPPesc regimens based on risk group. The primary endpoint was event-free survival (EFS), defined as disease progression or death from HL.

Results

Median age of patients at diagnosis was 29 years (range 18-50), 16 (28,5%) male and 40 (71,5%) pts were female. Bulky disease (>10 cm in any dimension) were presented in 6/56 (10,7%) of pts, B symptoms - in 16/56 (28,5%) and extranodal disease had 4/56 (7%). Median follow-up was 24 months from diagnosis. Interim PET (PET2) was performed in 50 pts at 15.5 ±3 days (range, 5-26) after 2xABVD or 2xBEACOPP esc cycles. Interim PET-CT was assessed as DS 1-2 in 34 patients (60,7%), DS 3 in 11 (19,6%), DS 4-5 in 5 pts (8,8%). In total, disease progression was documented in 5/56 (9%). Among them, 2/5 (40%) patient were PET2-positive (PET2+) and 3/5 (60%) PET2-negative (PET2-), (p > 0.05). There were no registered deaths from the refractory disease. We did not find any significant difference between EFS rate in pts with PET2+ vs PET2- (log-rank test, p = 0.4). 47 pts have proceeded for end-of-treatment PET-CT (PET3). Results showed 3/47 pts (6,3%) were PET3+ and PET3- were 44/47 (93,7%), (p < 0,05). EFS was compared and assessed depending on DS. Achieved rate of 3-year EFS in pts with PET3 DS 1-2, DS 3 and DS 4-5 were 94,4%, 50% and 0%, respectively (p < 0.006).

Conclusions

End of treatment PET-CT plays an important role in patients with early-stage HL and could be a beneficial prognostic factor. However, there is still need for prospective confirmation of interim PET-CT as a prognostic factor.

Clinical trial identification

Legal entity responsible for the study

Tetiana Skrypets.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.